Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1200 participants.
Also called NCT02430350
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,200 participants
- Registry
-
NCT02430350
-
- Other papers using this trial's data
- Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02430350. Randomized; quadruple masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2016-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Compound Edaravone Injection
- Intervention (Drug)
- Edaravone Injection
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct02430350- Content hash
78b016e51246b513b74b13b11d0c42bf61bfebc126fac7496d52ddedbac4f173